HTDK Participates in AdvaMed MedTech Conference 2025, Focusing on Global Innovation and Opportunities in the China Market

SAN DIEGO, Oct 8, 2025 — The AdvaMed MedTech Conference 2025, one of the world’s leading events for the medical technology industry, concluded successfully this week in San Diego.
As a leading provider of commercial solutions for high-value medical devices, HTDK participated in the conference with its core leadership team, led by CEO Teresa Chen and Board Director William Jin, to engage with global medtech executives and explore opportunities for innovation and collaboration in the China market.

During the conference, HTDK held in-depth discussions with senior executives from multinational medtech companies including Stryker, Zimmer Biomet, Hologic, and ZOLL Medical.

In recent years, the global medtech industry has been shaped by advances in AI-driven healthcare, precision surgery, remote care, and digital compliance management. Many multinational firms are reassessing their China operations—moving from wholly owned expansion models toward more flexible and collaborative local partnerships.

HTDK believes that China’s medical device sector is entering a new phase of high-quality growth, where competition will focus less on scale and more on efficiency and business model innovation.

“The past decade has been about establishing presence in China,” said CEO Teresa Chen. “The next decade will be defined by efficiency and model innovation. Our goal is to serve as a bridge connecting global innovation with the China market.”

At the conference, HTDK showcased its end-to-end service capabilities, spanning product registration, supply chain management, academic engagement, and compliance support.
The company’s “platform + customization” model provides global medtech firms with a one-stop solution—from market entry to sustainable local operations.

This approach drew significant attention at the event, particularly as many global companies are streamlining their China-based teams and seeking cost-effective, compliant, and scalable market solutions.

“We are seeing more multinational companies entrusting their China commercialization operations to specialized third-party platforms,” said Board Director William Jin. “to navigate geopolitical shifts and evolving market conditions.”

Widely regarded as a global barometer for the medtech industry, the AdvaMed MedTech Conference attracted participation from leading companies including Siemens Healthineers, GE HealthCare, and Boston Scientific.

Against this backdrop, China continues to be viewed as one of the most dynamic growth markets for medical technology commercialization.
HTDK’s experience demonstrates that as regulatory, policy, and reimbursement systems in China evolve, international companies are shifting their strategies from simple market entry to long-term strategic development.

“Success in China is no longer about just entering the market—it’s about finding the right operating model,” said Teresa Chen. “Those who can balance policy and execution will define the next cycle of growth.”